

Intuitive Surgical, Inc. (Nasdaq: ISRG) — Q2 FY2026 Results, FY2026 Outlook & Valuation

Fiscal second quarter ended June 30, 2026 · reported results, the company's own FY2026 outlook, and standard market-based valuation multiples. Intuitive pioneered robotic-assisted soft-tissue surgery (da Vinci, first FDA-cleared in 2000) and also makes the Ion endoluminal (lung-biopsy) system — sold on a razor/razor-blade model where ~84% of FY2025 revenue recurred.

A factual snapshot built from Intuitive's public filings — reported results, the company's own forward outlook, and public market data. It contains no Blackspear forecast, price target, or recommendation.

REVENUE (Q2'26)

\$2.89B

▲ 19% vs \$2.44B in Q2'25
recurring rev ~84% (FY2025)

NON-GAAP EPS — DIL.

\$2.80

▲ 28% vs \$2.19 in Q2'25
GAAP EPS \$2.29 (vs \$1.81)

WW PROCEDURES

≈ +16%

da Vinci ≈ +15%; Ion ≈ +36%
YoY volume growth

DA VINCI INSTALLED BASE

11,710

▲ 12% vs 10,488
+468 placed in the quarter

REVENUE BY TYPE — Q2 FY2026

REVENUE LINE	Q2'26	% TOT.	YOY
Instruments & accessories	\$1,734.9M	60%	+18%
Systems	\$685.0M	24%	+19%
Services	\$472.4M	16%	+21%
Total revenue	\$2,892.3M	100%	+19%

Instruments/accessories + services (~76% of revenue) are recurring and scale with the installed base and procedure volume; systems (~24%) is the more cyclical capital line. Recurring revenue was ~84% of the total in FY2025.

OPERATING DRIVERS — Q2 FY2026

METRIC	Q2'26	Q2'25
da Vinci systems placed	468	395
— of which da Vinci 5	246	180
Ion systems placed	55	54
Ion installed base	1,096	905
Non-GAAP gross margin	70.0%	67.9%

The da Vinci 5 flagship drove ~53% of da Vinci placements (246/468); it carries higher ASPs and ~11% higher utilization than da Vinci Xi (per Intuitive). Ion (lung biopsy) procedures grew ~36%. Non-GAAP operating income was \$1.22B (+29%).

FY2026 OUTLOOK — AS ISSUED WITH THE JULY 16, 2026 RELEASE

COMPANY FY2026 OUTLOOK

DA VINCI PROCEDURE GROWTH

13.5–15.5%

expects "closer to the midpoint"

NON-GAAP GROSS MARGIN

68.0–69.0%

incl. ~1.0% tariff headwind

NON-GAAP OPEX GROWTH

+11–13%

continued R&D and commercial investment

CONSENSUS (NON-GAAP EPS)

~\$10.79

FY26E Street est.
+21% vs FY25 \$8.93

Procedure / margin / opex framework — no EPS guidance

Intuitive does not issue EPS guidance; the EPS figure above is analyst consensus, not company guidance. The gross-margin range assumes tariffs currently in effect remain through year-end; further tariffs (Intuitive makes instruments in Mexico, endoscopes in Germany, and imports certain materials from China) "could be material." No forward GAAP reconciliation is provided.

VALUATION SNAPSHOT — AS OF AUGUST 7, 2026 CLOSE

Share price	~\$378.81	P / E (trailing, GAAP)	~43x
Market capitalization (~353.3M sh.)	~\$133.8B	Fwd P / E (FY26E non-GAAP \$10.79)	~35x
Cash & investments (no debt)	~\$8.63B	Fwd P / E (FY27E non-GAAP \$12.30)	~31x
Enterprise value (net of cash)	~\$125.2B	EV / Sales (FY26E ~\$11.8B)	~10.6x
Dividend / buyback	None / ~\$0.38B Q2	Consensus 12-mo target	~\$477 (rng \$324–\$685)
52-week range	\$328.57–\$603.88	Off Jan-2025 all-time high (~\$610)	≈ -38%

Multiples move with the share price — refresh before relying on them. The stock has de-rated hard: down ~38% from its January-2025 high even as revenue grew +19% and non-GAAP EPS +28% this quarter. Non-GAAP EPS excludes share-based comp of ~\$0.59/sh in Q2 (~21% of the \$2.80) — a real recurring cost; on a pre-SBC basis FY26E EPS is ~\$8.4 and the forward P/E is ~45x rather than ~35x. Consensus price targets are third-party analyst opinions, not Blackspear views. Intuitive is debt-free and returns cash via buybacks, not dividends.

WHAT'S MOST IMPACTFUL TO FUTURE EARNINGS

- **Installed-base recurring revenue.** Every system placed compounds recurring revenue (instruments per procedure + service). The da Vinci base grew 12% to 11,710 and Ion 21% to 1,096; ~84% of FY2025 revenue was recurring. Procedure growth (~16% WW) is the core earnings driver — more durable than lumpy system sales, provided Intuitive retains its share.
- **da Vinci 5 ramp.** 246 of 468 da Vinci placements were the new dv5 flagship (270,000+ procedures to date, 1,200+ installed, per Intuitive); higher ASPs lifted systems revenue and ~11% higher utilization than Xi supports future instrument pull-through. Cleared in the U.S., Korea, Japan and Europe.
- **Competition just arrived in the U.S.** In July 2026 J&J's Ottawa won U.S. FDA authorization — the first directly competitive multiport soft-tissue system to reach the U.S. market, alongside Medtronic's already-cleared Hugo (and domestic Chinese systems abroad) — ending da Vinci's two-decade U.S. soft-tissue monopoly and challenging Intuitive's ~80% share. Rivals still must scale and win indications, but the competitive set has changed.
- **Valuation is the swing factor.** At ~35x forward earnings (below its own historically richer multiple, but still a large premium) the stock is priced for durable ~15–20% growth; 2026's de-rating shows how much of the return rides on the multiple. Other risks: tariffs (~1.0% gross-margin drag), hospital capital-spending cycles, and large recurring SBC that non-GAAP EPS adds back.

HOW TO READ THE NUMBERS

- Non-GAAP EPS excludes SBC (~\$0.59/sh in Q2), intangible amortization, litigation and acquisition items. GAAP diluted EPS was \$2.29; both included a one-time \$0.08/sh IEEPA tariff-refund benefit.
- "Recurring revenue" = instruments & accessories plus services (~76% of Q2 revenue, ~84% for FY2025); it scales with procedures and the installed base. "Systems" (~24%) is the cyclical capital line.
- Procedure growth and installed base are the leading indicators analysts watch — they drive future recurring revenue more than any single quarter's system count.
- FY2026 outlook covers procedures, gross margin and opex only; Intuitive issues no EPS guidance, so the forward EPS shown is analyst consensus.

Full Excel model — linked tabs (historicals, procedure/installed-base detail, valuation, source tie-outs) — available on request. Email info@blackspearllc.com for a copy.


Important disclosures. This material is provided by Blackspear, LLC for general informational and educational purposes only. It is not investment, legal, tax, or accounting advice, is not a research report, and is not an offer, solicitation, or recommendation to buy, sell, or hold any security. Blackspear, LLC is not a registered investment adviser or broker-dealer. Information is drawn from sources believed reliable — principally Intuitive Surgical's public filings (the earnings release, financial supplement and Form 10-Q for the fiscal quarter ended June 30, 2026, and the Q2 2026 investor presentation dated July 16, 2026) and public market data as of August 7, 2026 — but its accuracy, completeness, and timeliness are not guaranteed and it may contain errors or become outdated. "Non-GAAP" gross margin, operating income, net income and EPS are non-GAAP measures as defined by Intuitive; they exclude share-based compensation and long-term incentive plan expense (a significant, recurring expense), intangible amortization, litigation, acquisition-related and certain tax items, and are not substitutes for GAAP measures and may not be comparable to similarly named measures at other companies. GAAP diluted EPS was \$2.29 for the fiscal second quarter of 2026. The FY2026 outlook is Intuitive's own and covers procedures, gross margin and operating-expense growth only; Intuitive does not provide EPS guidance, and forward EPS figures shown are third-party analyst consensus, which is inherently uncertain and subject to revision. Forward-looking figures are subject to risks and uncertainties described in Intuitive's filings — including tariffs, competition, hospital capital spending, regulatory clearances, supply chain, and legal proceedings; actual results may differ materially. Past performance and historical valuation relationships are not indicative of future results. Recipients should independently verify all figures against the primary filings and consult their own advisers before making any decision. Blackspear, LLC and its principals may hold positions in the securities mentioned and undertake no obligation to update this material.

Intuitive Surgical, Inc. (Nasdaq: ISRG) — Valuation vs. Forward Growth

Price vs. earnings-justified value on ISRG's reported non-GAAP EPS, judged against forward EPS-growth consensus. Non-GAAP EPS has compounded ~24%/yr; the stock's 2026 fall is largely a multiple reset — though the competitive set has just changed.

History from ISRG disclosures and public market data; forward EPS estimates are analyst consensus; P/E, PEG and earnings-justified reference lines are Blackspear calculations. Reference lines are mechanical, not a Blackspear price target or recommendation.

PRICE VS. EARNINGS-JUSTIFIED VALUE — ISRG NON-GAAP EPS, FY2022–FY2027E



VALUATION & GROWTH

Current price (7 Aug 2026)	~\$378.81
Forward P/E (FY26E \$10.79)	~35×
Forward P/E (FY27E \$12.30)	~31×
Trailing P/E (GAAP)	~43×
Non-GAAP EPS: FY22 → FY26E	\$4.68 → \$10.79
Consensus EPS growth (FY26 / FY27)	~+21% / +14%
Forward PEG (fwd P/E ÷ FY26E growth)	~1.7×
Off Jan-2025 ATH (~\$610) / dividend	≈ ~38% · none

DOES FORWARD GROWTH JUSTIFY THE MULTIPLE?

STRONG RESULTS, A RESET MULTIPLE — AND NEW COMPETITION

The de-rating is mostly multiple, not earnings

Non-GAAP EPS compounded ~24%/yr (FY22–25) and Q2 delivered +19% revenue / +28% EPS, so 2026's ~38% drawdown is largely multiple compression: ~35× forward is below Intuitive's historically richer multiple (its forward P/E generally ran in the ~40s–50s in prior years; trailing ~60–80×). But the premium is still large and the setup has changed — in July 2026 J&J's Ottawa won U.S. FDA authorization (joining Medtronic's Hugo), challenging Intuitive's ~80% share. At ~35× forward / ~10.6× sales the stock still embeds durable high-teens growth; analyst targets span ~\$324–\$685 (consensus ~\$477). This lays out both sides; it is not a Blackspear view.

The catch: the bull read (a reset multiple on a compounding, ~84%-recurring franchise) and the bear read (a still-premium multiple, now-cleared competitors that must scale, hospital-capex cycles, tariffs, and a large SBC add-back of ~\$0.59/sh) both hold. The reference lines are illustrative, not a target.

REVENUE & RECURRING-REVENUE QUALITY — FY2021–FY2026E



Revenue (\$B) compounded from ~\$5.7B (FY2021) to ~\$10.1B (FY2025), ~15% CAGR; FY2026E consensus ~\$11.8B. Recurring revenue (instruments & accessories + services) rose from ~75% of the total (2021) to ~84% (2025) as the installed base grew to 12,000+ Intuitive systems. FY2026E is analyst consensus; 2026E bar shown lighter.

On forward estimates. Forward non-GAAP EPS of ~\$10.79 (FY2026) and ~\$12.30 (FY2027) are analyst consensus (Intuitive issues no EPS guidance). Non-GAAP EPS excludes share-based compensation — ~\$0.59/sh in Q2 2026, ~21% of that quarter's \$2.80 — a real recurring cost; on a pre-SBC basis the forward P/E is ~45× rather than ~35×. P/E, PEG, EV/Sales and the earnings-justified reference lines are mechanical Blackspear calculations — not estimates, price targets, or recommendations. Consensus estimates are inherently uncertain and subject to revision.

Important disclosures. This material is provided by Blackspear, LLC for general informational and educational purposes only. It is not investment, legal, tax, or accounting advice, is not a research report, and is not an offer, solicitation, or recommendation to buy, sell, or hold any security. Blackspear, LLC is not a registered investment adviser or broker-dealer. Non-GAAP EPS figures for fiscal 2022–2025 are Intuitive Surgical's own reported non-GAAP results from its full-year earnings releases; the fiscal 2026 and 2027 figures are analyst consensus obtained from public sources and are inherently uncertain, may be revised, and actual results may differ materially. Revenue figures are as reported (2021–2025) and consensus (2026E). Share prices and annual trading ranges are public market data; the annual ranges shown are approximate intraday highs and lows and the current price is the August 7, 2026 close. Price-to-earnings ratios, PEG ratios, EV/Sales, and the earnings-justified reference lines (35× and 50× non-GAAP EPS) are Blackspear calculations using standard methods and are mechanical, illustrative constructs, not a Blackspear valuation, forecast, price target, or recommendation; the 35×/50× band is an illustrative range chosen to bracket the current, post-de-rating price; it sits below Intuitive's historical forward multiple (its forward P/E generally ran in the ~40s–50s, and trailing P/E ~60–80×, over 2020–2025) and does not represent a historical average. Comparisons of current forward multiples to prior-period trailing multiples are not like-for-like. "Non-GAAP" measures are defined by Intuitive, exclude share-based compensation and other items, and may not be comparable to similarly named measures at other companies. Intuitive pays no dividend and returns capital via share repurchases. Past performance and historical valuation relationships are not indicative of future results. Recipients should independently verify all figures against the primary sources and consult their own advisers before making any decision. Blackspear, LLC and its principals may hold positions in the securities mentioned and undertake no obligation to update this material.